Autolus Therapeutics plc SEC filings AUTL
Autolus Therapeutics plc has 336 filings in SEC EDGAR's recent list, going back to Feb 9, 2018. Its latest annual report, Form 10-K, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Sep 22, 2026 | — |
| DEL AM | Filing | Sep 15, 2026 | — |
| EFFECT | Filing | May 5, 2026 | — |
| EFFECT | Filing | May 5, 2026 | — |
| CORRESP | Letter to the SEC | May 1, 2026 | — |
| CORRESP | Letter to the SEC | May 1, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 15, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 15, 2026 | — |
| DEL AM | Filing | Apr 15, 2026 | — |
| DEL AM | Filing | Apr 15, 2026 | — |
| EFFECT | Filing | May 15, 2025 | — |
| CORRESP | Letter to the SEC | May 13, 2025 | — |
| UPLOAD | Letter from the SEC | May 12, 2025 | — |
| EFFECT | Filing | Mar 21, 2025 | — |
| POSASR | Filing | Mar 20, 2025 | — |
| UPLOAD | Letter from the SEC | Nov 7, 2024 | — |
| CORRESP | Letter to the SEC | Sep 30, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 19, 2024 | — |
| NT 10-Q | Filing | May 13, 2024 | May 13, 2024 |
| D | Filing | Feb 23, 2024 | — |
| EFFECT | Filing | May 17, 2022 | — |
| CORRESP | Letter to the SEC | May 13, 2022 | — |
| UPLOAD | Letter from the SEC | May 9, 2022 | — |
| EFFECT | Filing | Apr 28, 2022 | — |
| CORRESP | Letter to the SEC | Apr 26, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 20, 2022 | — |
| EFFECT | Filing | Aug 18, 2021 | — |
| CORRESP | Letter to the SEC | Aug 16, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 12, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 9, 2020 | — |
| CORRESP | Letter to the SEC | Jun 30, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 18, 2020 | — |
| EFFECT | Filing | Jul 24, 2019 | — |
| CORRESP | Letter to the SEC | Jul 22, 2019 | — |
| UPLOAD | Letter from the SEC | Jul 22, 2019 | — |
| EFFECT | Filing | Apr 10, 2019 | — |
| CORRESP | Letter to the SEC | Apr 8, 2019 | — |
| CORRESP | Letter to the SEC | Apr 8, 2019 | — |
| UPLOAD | Letter from the SEC | Nov 29, 2018 | — |
| DRS | Filing | Nov 23, 2018 | — |
| CT ORDER | Filing | Jun 22, 2018 | — |
| EFFECT | Filing | Jun 21, 2018 | — |
| EFFECT | Filing | Jun 21, 2018 | — |
| CERT | Filing | Jun 20, 2018 | — |
| CORRESP | Letter to the SEC | Jun 19, 2018 | — |
| CORRESP | Letter to the SEC | Jun 19, 2018 | — |
| 8-A12B | Filing | Jun 19, 2018 | — |
| CORRESP | Letter to the SEC | Jun 19, 2018 | — |
| UPLOAD | Letter from the SEC | Jun 15, 2018 | — |
| CORRESP | Letter to the SEC | Jun 8, 2018 | — |
| CORRESP | Letter to the SEC | May 30, 2018 | — |
| UPLOAD | Letter from the SEC | May 17, 2018 | — |
| CORRESP | Letter to the SEC | May 10, 2018 | — |
| UPLOAD | Letter from the SEC | May 8, 2018 | — |
| DRSLTR | Filing | Apr 27, 2018 | — |
| DRS/A | Filing | Apr 27, 2018 | — |
| UPLOAD | Letter from the SEC | Apr 9, 2018 | — |
| DRS/A | Filing | Mar 23, 2018 | — |
| DRSLTR | Filing | Mar 22, 2018 | — |
| UPLOAD | Letter from the SEC | Mar 9, 2018 | — |
| DRS | Filing | Feb 9, 2018 | — |
Showing 61 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- AUTL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- London, United Kingdom
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1730463
- Former names
- Autolus Therapeutics Ltd (until Jun 8, 2018)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.